Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
Date:1/5/2009

SAN CARLOS, Calif., Jan. 5 /PRNewswire-FirstCall/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 27th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel on Tuesday, January 13, 2009 at 10:00 a.m. Pacific time (1:00 p.m. Eastern time).

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until February 15, 2009.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its advanced polymer conjugate technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. For more information on Nektar Therapeutics, please visit http://www.nektar.com.

     Nektar Contacts:
     Jennifer Ruddock
     Nektar Therapeutics
     650-631-4954
     jruddock@nektar.com

     Susan Noonan
     The SAN Group
     212-966-3650
     susan@sanoonan.com

'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
2. Nektar Therapeutics to Webcast R&D Day on November 12th
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
6. Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets
7. Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
8. Nektars PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
9. Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
10. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
11. West Concludes Agreement with Nektar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2020)... , ... June 26, 2020 , ... ... representing security solutions providers, today announced its strong opposition to the recently introduced ... would impose a blanket ban on most federal use of nearly all biometric ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... complex indoor environments, announced today that Derek Fournier has been appointed CEO and ... of the Board, effective immediately. , “DeCurtis Corporation has been on an ...
(Date:6/23/2020)... , ... June 22, 2020 , ... ... glutamine antagonist, DRP-104, will be presented June 22-24 during the American Association for ... DRP-104; and, the other profiles the potent, consistent single agent activity in KEAP1 ...
(Date:6/19/2020)... (PRWEB) , ... June 18, 2020 , ... The ... Its goal is to join forces to radically prolong life and find a way ... the aging period. This project was supported by various scientists from all over the ...
Breaking Biology Technology:
(Date:5/28/2020)... ... May 28, 2020 , ... ... enzyme solution for adjunct liquefaction: AMYLEX® 6T. The innovative enzyme enables numerous ... into new segments with locally-sourced raw materials, improve productivity, maximize yield, ensure ...
(Date:5/26/2020)... FRANCISCO (PRWEB) , ... May ... ... provider of enterprise software solutions for biopharmaceutical R&D, today announced that Gritstone ... of T-cell receptor (TCR)-mimetic bispecific T cell engagers and TCR-based therapeutics, has ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... technology-based services specializing in background and medical screening, announces the launch of ... and keeping their workforce safe. The new service is provided by ClearStar’s ...
Breaking Biology News(10 mins):